Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15119450 | 0.94 | CTSV (0.35) | MAPK1HSD17B10KDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL14646354 | 0.92 | HSD17B10 (0.34) | MAPK1HSD17B10MEN1KMT2AHTT | |
| SCHEMBL14646346 | 0.88 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL15119446 | 0.88 | HSD17B10 (0.45) | HSD17B10HTT | |
| SCHEMBL15120673 | 0.85 | MAPK1 (0.35) | MAPK1MEN1KMT2AHTT | |
| SCHEMBL3385012 | 0.81 | ALDH1A1 (0.41) | MAPK1KDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL8526510 | 0.78 | MAPK1 (0.36) | MAPK1MEN1KMT2AHTT | |
| SCHEMBL9187798 | 0.78 | MAPK1 (0.36) | MAPK1MEN1KMT2AHTT | |
| SCHEMBL9475504 | 0.78 | KDM4E (0.30) | KDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL9188490 | 0.78 | MAPK1 (0.36) | MAPK1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013009800-A2 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | MAPK1 4223/4885HSD17B10 3622/4885KDM4E 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.